These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Vascular damage in chronic kidney disease]. Jara A; Mezzano S Rev Med Chil; 2008 Nov; 136(11):1476-84. PubMed ID: 19301781 [TBL] [Abstract][Full Text] [Related]
24. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Ueda S; Yamagishi S; Kaida Y; Okuda S Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585 [TBL] [Abstract][Full Text] [Related]
25. [Experimental study of the mechanism for vascular calcification in chronic kidney disease]. Persy V Verh K Acad Geneeskd Belg; 2008; 70(4):285-303. PubMed ID: 19166100 [TBL] [Abstract][Full Text] [Related]
26. Pathophysiological mechanisms and consequences of cardiovascular calcifications: role of uremic toxicity. Chillon JM; Mozar A; Six I; Maizel J; Bugnicourt JM; Kamel S; Slama M; Brazier M; Massy ZA Ann Pharm Fr; 2009 Jul; 67(4):234-40. PubMed ID: 19596096 [TBL] [Abstract][Full Text] [Related]
27. Cardiovascular effects of uremia in apolipoprotein E-deficient mice. Bro S Dan Med Bull; 2009 Nov; 56(4):177-92. PubMed ID: 19939336 [TBL] [Abstract][Full Text] [Related]
28. The renal patient with cardiovascular disease--no longer a simple plumbing problem. Tunuguntla A; Yerra L Tenn Med; 2005 Aug; 98(8):395-6, 399. PubMed ID: 16315466 [TBL] [Abstract][Full Text] [Related]
29. Arterial stiffness and pulse pressure in CKD and ESRD. Briet M; Boutouyrie P; Laurent S; London GM Kidney Int; 2012 Aug; 82(4):388-400. PubMed ID: 22534962 [TBL] [Abstract][Full Text] [Related]
30. Vascular disease and atherosclerosis in uremia. London GM Nefrologia; 2005; 25 Suppl 2():91-5. PubMed ID: 16050410 [TBL] [Abstract][Full Text] [Related]
31. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Kestenbaum B Semin Dial; 2007; 20(4):286-94. PubMed ID: 17635817 [TBL] [Abstract][Full Text] [Related]
36. Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Schepers E; Glorieux G; Dou L; Cerini C; Gayrard N; Louvet L; Maugard C; Preus P; Rodriguez-Ortiz M; Argiles A; Brunet P; Cohen G; Jankowski J; Jankowski V; Massy Z; Rodriguez M; Vanholder R; Blood Purif; 2010; 30(4):277-87. PubMed ID: 21079396 [TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Peiskerová M; Kalousová M; Kratochvílová M; Dusilová-Sulková S; Uhrová J; Bandúr S; Malbohan IM; Zima T; Tesar V Kidney Blood Press Res; 2009; 32(4):276-83. PubMed ID: 19797911 [TBL] [Abstract][Full Text] [Related]